Physicochemical Properties
| Molecular Formula | C28H27BRNO3P |
| Molecular Weight | 536.396647691727 |
| Exact Mass | 535.091 |
| CAS # | 1254044-41-1 |
| PubChem CID | 49802132 |
| Appearance | Light yellow to yellow solid powder |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 8 |
| Heavy Atom Count | 34 |
| Complexity | 550 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | [Br-].[P+](C1C=CC=CC=1)(C1C=CC=CC=1)(C1C=CC=CC=1)CCNC(C1C=CC(=C(C=1)OC)O)=O |
| InChi Key | VCBKDUGPZYICTB-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C28H26NO3P.BrH/c1-32-27-21-22(17-18-26(27)30)28(31)29-19-20-33(23-11-5-2-6-12-23,24-13-7-3-8-14-24)25-15-9-4-10-16-25;/h2-18,21H,19-20H2,1H3,(H-,29,30,31);1H |
| Chemical Name | 2-[(4-hydroxy-3-methoxybenzoyl)amino]ethyl-triphenylphosphanium;bromide |
| Synonyms | Mitoapocynin (C2); Mito apocynin (C2) |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vivo | It is possible to achieve anti-neuroinflammatory effects using mito-apocynin (C2) (3 mg/kg; oral; once daily for 12 days) [1]. |
| Animal Protocol |
Animal/Disease Models: Parkinson's disease MPTP mouse model [1] Doses: 3 mg/kg Route of Administration: po (oral gavage); one time/day for 12 days Experimental Results: Dramatically attenuated MPTP-induced glial cell activation and pro-inflammatory cells Factor upregulation, inducible nitric oxide synthase and NOX2 components (gp91phox). |
| References |
[1]. Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. Chem Rev. 2017 Aug 9;117(15):10043-10120. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~100 mg/mL (~186.43 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.66 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (4.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8643 mL | 9.3214 mL | 18.6428 mL | |
| 5 mM | 0.3729 mL | 1.8643 mL | 3.7286 mL | |
| 10 mM | 0.1864 mL | 0.9321 mL | 1.8643 mL |